1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinibJ. De Langen, Helena A. Yu, Sarah B. Goldberg et al.|Annals of Oncology|2022Cited by 7
329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinibJonathan W. Riess, H.A. Yu, J.A. De Langen et al.|Annals of Oncology|2022Cited by 4